Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ephedra Label Warning With Limited PDP Statement Recommended By CRN

This article was originally published in The Tan Sheet

Executive Summary

The Council for Responsible Nutrition suggests FDA require a label warning format for ephedrine alkaloid-containing products featuring a limited principal display panel declaration that refers consumers to more information on another part of the label

You may also be interested in...

Ephedra “Black Box” Warning Considered By FDA

FDA is suggesting that a "black box" warning appear on the principal display panel of all ephedrine alkaloid-containing dietary supplements, FDA Commissioner Mark McClellan, MD/PhD, said during a Feb. 28 briefing held in Washington, D.C

Ephedrine Alkaloid Sensitivity Study Urged By Researchers Boozer, Daly

A large, case-control study may be necessary to determine whether some people have unusually high sensitivity to the potential adverse effects of ephedrine alkaloids, researchers say in the May issue of the International Journal of Obesity

Ephedra/AER Causality Link Not Possible - Cantox/CRN

Ephedrine alkaloid adverse event reports recorded in FDA's Special Nutritional Adverse Event Monitoring System do not establish causation between supplements containing the popular weight loss and sports herbal ingredient and reported AEs, according to a report commissioned by the Council for Responsible Nutrition.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts